EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Listening to Leading: Reimagining HEOR Through the Lens of Patient-Centred Evidence
Co-Founder & Director, MarksMan Healthcare
Dimple Dang CoFounder of MarksMan Healthcare is a strategic growth architect shaping the firms global footprint She forges highimpact collaborations leads business expansion and builds a talent ecosystem aligned with excellence Her leadership elevates credibility strengthens brand equity and positions MarksMan as a trusted strategic partner delivering value across global healthcare markets
Articles
Your biosimilar, your journey, Sponsored Content by Cytiva
For biosimilar developers stars are now within reach With blockbuster drug patents for more than billion in annual revenue set to expire by theres a world of opportunities on the horizon To be successful developers must carefully consider
Research Insights
Host Centric Drug Repurposing for Viral Diseases
Computational approaches for drug repurposing for viral diseases have mainly focused on a small number of antivirals that directly target pathogens virus centric therapies In this work we combine ideas from collaborative
Case Studies
Cyclodextrins as Active Pharmaceutical Ingredients for The Treatment Of GM1-Gangliosidosis: A Feasibility Case Study
Abstract GMgangliosidosis is a rare lysosomal storage disorder characterized clinically by a wide range of variable neurovisceral ophthalmological and dysmorphic features Without enough functional galactosidase GMgangliosides cannot be degraded in lysosomes and accumulate to toxic levels in many tissues and organs particularly in the brain In s
Techno Trends
China's New Drug Approval Process Streamlined to Boost Biopharma Innovation
China has revised its drug approval process aiming to expedite the launch of innovative biopharmaceuticals
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Green Revolution in Medicine
Dr Aishwarya Jain is an Assistant Professor and award-winning pharmaceutical researcher recognised with over 70+ national and international honours. Her research focuses on green synthesis, nanotechnology, and sustainable drug delivery. A SCOPUS journal editor and published author, she is dedicated to advancing eco-friendly pharmaceutical innovation and inspiring the next generation of researchers.
Six Sigma - Time, cost and product quality improvement
Ashwin Kuchekar is an Associate Professor and the Head of Career Services and Placement at the School of Pharmacy, Dr. Vishwanath Karad MIT-WPU in Pune. He completed his M. Pharm.in 2009 and Ph. D. in 2015. In 2012, he received the Senior Research Fellow (SRF) Award from the Council of Scientific Industrial and Research (CSIR). He is a trained specialist in Lean Six Sigma Black Belt (LSSBB). He has 7 years of industrial experience in reputed pharmaceutical companies such as Piramal, Lupin, and Abbott Healthcare. He has a unique blend of statistics and formulation development, Quality by Design with exposure to branded and generic product development. He has practical experience in the Design of Experiments and product formulation and process optimisation.
Alpha-fetoprotein as a Shuttle for Medicines
Vladimir Pak received his Ph.D. from the Institute of Bioorganic Chemistry, Moscow. He modernized technologies and manufactured APIs for the known drugs. Invented anticancer drug candidates based on alpha-fetoprotein that can be used as injectable or orally. Developed supplements to treat stomach ulcers and IBD.
Green Synthesis of Metallic Nanoparticles
Ms. Aishwarya Jain is a distinguished pharmaceutical scientist and academician with over six years of experience in pharmaceutical sciences. Currently serving as an Assistant Professor at Sinhgad College of Pharmacy, Vadgaon (Bk), Pune, she has carved a niche for herself in the domains of nanotechnology, green synthesis, and pharmaceutical innovation.
A recipient of 65+ prestigious national and international awards, including the Bharat Shiksha Gaurav Puraskar and the Women Empowerment Award, Ms. Jain is recognised as one of the leading voices in pharmaceutical education and research. Her scholarly contributions span numerous books, book chapters, and high-impact research articles published in top-tier journals indexed in SCOPUS and Web of Science.
Renowned for her commitment to academic excellence and research integrity, she also plays an active role as an editorial board member and peer reviewer for reputed scientific journals and publishing houses. Her work exemplifies a seamless blend of academic rigor and innovative thinking, particularly in green nanotechnology and sustainable drug development.
Driven by a vision to advance pharmaceutical science for global health impact, Ms. Aishwarya continues to inspire through her interdisciplinary collaborations, cutting-edge research, and passionate teaching.
Detangling the Diagnostic Odyssey in Neurodevelopmental Disorder by Genomic Consultancy
Emili is a well-known genetic consultant with vast experience in cytogenetics, molecular biology with special emphasis in neurobiology. She is doing human genetics for past 22 years and now is practising genetic counselling as well as continuing her passion for research.
Koutilya basically is an academician in Zoology and has research interest in areas like anti-microbial peptides of amphibians, bio-active components of amphibians and genetic aspects of human reproductive disorder.
press releasesRead more...
Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
Samsung Bioepis and Organon a global healthcare company with a deep expertise in biosimilars announced the expansion of their development and commercialization agreement whereby Organon will obtain commercialization
Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
Chai Discovery the AI company engineering models to discover new molecules today announced that certain Chai Discovery frontier AI model capabilities will be made available to companies participating in the Lilly TuneLab platform
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
Charles River Laboratories International Inc NYSE CRL announced a collaboration with Lilly TuneLab a collaborative AIML drug discovery platform created by Eli Lilly and Company Lilly
Cold Chain Technologies Launches CCT Rx Secure to Streamline Specialty Pharmacy Shipments
Cold Chain Technologies has launched CCT Rx Secure a new digital application designed to support specialty pharmacies in making more informed repeatable packout decisions for temperaturesensitive shipments
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Roche SIX RO ROP OTCQX RHHBY announced today that the US Food and Drug Administration FDA has accepted the companys supplemental Biologics License Application sBLA for Lunsumio VELO
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Oncotelic Therapeutics Inc Oncotelic or the Company OTCQB OTLC today announced the completion of key Phase objectives in its joint manufacturing automation initiative with TechForce Robotics Inc
EventsRead more...
18 - 20
Jun 2026CCT 2026
Barcelona, Spain
23 - 24
Jun 2026Supply Chain USA 2026
Chicago, IL
24 - 25
Jun 20266th Edition Drug Safety Symposium 2026
Courtyard by Marriott, Mumbai,...
25 - 26
Jun 2026Pharmacology and Toxicology 2026
Paris, France
07 - 09
Jul 2026The Pharma India Expo 2026
Bombay Exhibition Centre, Mumb...
07 - 09
Jul 2026Nanosciences and Nanotechnologies 2026
Thessaloniki, Greece
08 - 10
Jul 2026CPHI SEA 2026
QSNCC, Bangkok, Thailand
09 - 11
Jul 2026Pharma Pro&Pack Expo 2026
HITEX Exhibition Centre, Hyder...
LATEST NEWSRead more...
SK pharmteco Partners with OTXL to Advance Rare Disease Therapies
SK pharmteco has entered into a strategic collaboration with the Orphan Therapeutics Accelerator OTXL to support the development and manufacturing of treatments for rare diseases
Boltz Collaborates with Takeda to Expand Use of Biomolecular AI Models in Drug Discovery
Boltz PBC has announced a collaboration with Takeda to deploy its advanced biomolecular artificial intelligence models and platform across Takedas research organisation
Insilico Reaches First Clinical Milestone for AI-Developed NLRP3 Inhibitor ISM8969
Insilico Medicine has completed firstinhuman dosing in the Phase I clinical study of ISM marking the first clinical milestone in its codevelopment partnership with Hygtia Therapeutics ISM is an orally administered
Biogen to Acquire RayThera to Strengthen Immunology Pipeline
Biogen has entered into a definitive agreement to acquire RayThera Inc a privately held biotechnology company focused on developing smallmolecule therapies for immunological diseases The deal is valued at up to billion
Jazz Pharmaceuticals and AbCellera Partner to Develop Next-Generation T-Cell Engaging Antibodies for Cancer
Jazz Pharmaceuticals and AbCellera have entered into a preclinical research collaboration option and licence agreement to discover and develop nextgeneration Tcell engaging TCE multispecific antibodies for gastrointestinal GI cancers and other solid tumours
Lilly Acquires 4E Therapeutics to Advance Non-Opioid Chronic Pain Treatments
Eli Lilly and Company has acquired E Therapeutics an Austinbased neuroscience company focused on developing nonopioid treatments for chronic pain Financial terms of the transaction were not disclosed